This is to inform that due to some circumstances beyond the organizer control, “2nd Edition of International Conference on Gastroenterology” (Gastro 2024) during October 21-23, 2024 at Baltimore, MD, USA has been postponed. The updated dates and venue will be displayed shortly.
Your registration can be transferred to the next edition, if you have already confirmed your participation at the event.
For further details, please contact us at gastroenterology@magnusconference.com or call + 1 (702) 988-2320.
Hepatic hemangiomas are benign tumors that develop in the liver and may not cause any symptoms. These tumors are formed from a collection of extra blood vessels, and are the most common type of benign liver tumor. They can range in size from a few millimeters to several centimeters, and are typically located near the surface of the liver. Hepatic hemangiomas can be detected through imaging tests such as ultrasound, CT scans, and MRI scans. If the tumor is large enough, it may be visible on abdominal X-rays. In some cases, a biopsy may be necessary to confirm the diagnosis. Most hepatic hemangiomas do not require treatment and may shrink over time on their own. However, if the tumor is causing pain or discomfort, surgery may be an option to remove it. Some medications such as corticosteroids or interferon can also be used to shrink the tumor or reduce its symptoms. In rare cases, hepatic hemangiomas can become cancerous. This is why it is important to have regular check-ups with your doctor to monitor the size and growth of the tumor. If there are any changes in size or appearance of the tumor, it should be evaluated promptly. Hepatic hemangiomas are generally not dangerous and do not cause any long-term health problems. However, they should still be monitored closely by your doctor so that any changes can be detected early and appropriate treatment can be started if necessary.
Title : Novel exosomal biomarkers for MASH
Aleksandra Leszczynska, University of California San Diego, United States
Title : Validation of GLAS (GP73+LG2m+Age+Sex) and ASAP (Age+Sex+AFP+PIVKA-II) algorithms for the management of liver fibrosis, cirrhosis and cancer
Philip M Hemken, Abbott Diagnostics Division R&D, United States
Title : Reverse multiple myeloma: First hepatic amyloidosis then multiple myeloma
Milaris M Sanchez Cordero, Mayaguez Medical Center, Puerto Rico
Title : Autophagy promotes the survival of adipose mesenchymal stem/stromal cells and enhances their therapeutic effects in cisplatin-induced liver injury via modulating TGF-1/Smad and PI3K/AKT signaling pathways
Eman Mohamad EL Nashar, King Khalid University, Saudi Arabia
Title : Epigastric Impedance measures gastric malfunction non-invasively. Time to revive it
John Andrew Sutton, Gastria Ltd, United Kingdom
Title : Digesting the connection: Exploring the psychological impact of gastroenterology issues on mental and emotional well being
Tracy E Hill, MGS Products LLC, United States